AstraZeneca(US:AZN) Xin Hua She·2026-01-20 09:27Core Viewpoint - AstraZeneca views China as a critical global strategic market and innovation hub, highlighting the country's market size, business environment, and innovation capabilities as key factors attracting investment [2]. Group 1: Investment and Market Presence - AstraZeneca has invested over $5 billion in China since entering the market in 1993, establishing a comprehensive industry chain that includes research, production, and commercial operations [2]. - China has become AstraZeneca's second-largest market globally, significantly supporting the company's global research efforts and playing a vital role in the international pharmaceutical supply system [2]. Group 2: Research and Development - In the past four years, the number of drugs under research in China has doubled, with approximately one-third of global drug authorization transactions involving Chinese biopharmaceutical companies, indicating China's growing importance in global business expansion for multinational companies [3]. Group 3: Business Environment and Policy Support - A favorable business environment and a rich talent pool are crucial for multinational companies to invest, collaborate, and develop long-term in China [4]. - The "14th Five-Year Plan" signals China's commitment to high-level opening-up and presents new opportunities for economic growth, fostering confidence among multinational companies regarding China's long-term development prospects and business environment [4].